Global Skin Cancer Vaccine Market & Pipeline Insight 2015

Description: Skin cancer incidences are increasing at alarming rates across the world causing high morbidity and mortality. Research and development in field is expected to change the present scenario by providing better therapeutic options for patients. Skin cancer therapeutics available in market used for first-line treatment have modest efficacy which lays emphasis on the development of better products like skin cancer vaccines. Cancer vaccines for different disease indications have proved their worth in medical fraternity by providing better safety and efficacy profiles. Skin cancer vaccines based products are not available in market but they are soon expected to be entering in market in coming years. Market introduction of such products is much awaited to fulfill the unmet medical demand.

Skin cancer vaccine category seems to be one of the most advanced drug category in terms of number of products and types of products. Efforts in this field have allowed the investigators to come with new ideas like implants and oncolytic viruses for the treatment of skin cancer. Such dichotomy is not observable in other cancer categories due to which this segment is expected to occupy significant market share. Also, among different cancer products this skin cancer is expected to generate more revenues in coming years. Initially, it is expected that skin cancer vaccines would be used in combinatorial therapy with conventionally available drugs before becoming main stream treatment. Owing to better pharmacological profiles they are expected to become regular component of therapeutic regime.

Novelty of skin cancer vaccine design is expected to be the major factor in increasing their market penetration. Oncolytic skin cancer vaccines are much awaited products as they have no competitors in present market. Theoretically, they can cure skin cancer at advanced stages and increase the life span of patients but they still needs to be investigated rigorously in clinical trials before market introduction. Skeptics and many medical professional show concern about use of oncolytic viruses as they have pathogenic background and mutate to wild type causing infection in patients. However, such phenomenon has not been observed due to advanced genetic engineering and strict quality control during skin cancer vaccine production. Some of these products are at advanced phases of clinical trials meeting predefine end points for qualifying as a viable pharmacological option.

Implant section of skin cancer vaccine is also expected to make significant impact by decreasing present mortality and morbidity rates. Concept and therapeutic products using implants for treatment has been in pharmaceutical market for several decades. They tend to be more comfortable, require less visits to physicians and higher cost arbitrage coupled with improved technological advancements. This gives a notion that skin cancer vaccines implants will get higher acceptance rates as compared to oncolytic virus based products. However, it should not be compared in case of pharmacological effects because this depends on patients' medical condition and oncologists' discretion to utilize best product according to necessity.

“Global Skin Cancer Vaccine Market & Pipeline Insight 2015” Report Highlight

- Introduction to Skin Cancer Vaccine
- Global Skin Cancer Vaccine Market Analysis
- Global Skin Cancer Vaccine Pipeline by Company & Phase
- Global Skin Cancer Vaccine Pipeline: 47 Vaccines
- Majority Skin Cancer Vaccines in Phase-I: 12 Vaccines
- Marketed Skin Cancer Vaccines: 2 (MVax by AVAX Technologies & Melacine by GlaxoSmithKline)
- Personalized Cancer Vaccines: Progress & Possibilities
- Skin Cancer Vaccine Mechanism

Contents: 1. Introduction to Cancer Vaccines

2. Cancer Vaccines: Mechanism & Innovations
   2.1 Idiotype Cancer Vaccine Mechanism
   2.2 Cellular Cancer Vaccines Mechanism
   2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
   2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Introduction to Skin Cancer Vaccine

4. Skin Cancer Vaccine Mechanism

5. Global Skin Cancer Vaccine Market Overview
   5.1 Current Market Scenario
   5.2 Global Skin Cancer Vaccines Pipeline Overview

6. Global Skin Cancer Vaccine Market Dynamics
   6.1 Favorable Market Parameters
   6.2 Commercialization Challenges

7. Personalized Cancer Vaccines: Progress & Possibilities

8. Global Skin Cancer Vaccines Market Future Prospects

9. Global Skin Cancer Vaccine Pipeline by Company & Phase
   9.1 Preclinical
   9.2 Clinical
   9.3 Phase-I
   9.4 Phase-I/II
   9.5 Phase-II
   9.6 Phase-III

10. Marketed Skin Cancer Vaccines Clinical Analysis
   10.1 Melanoma Vaccine (MVax®, AVAX Technologies)
   10.2 Melanoma Vaccine (Melacine®, GlaxoSmithKline)

11. Suspended & Discontinued Skin Cancer Vaccines Pipeline by Company & Phase
   11.1 No Development Reported
   11.2 Discontinued

12. Competitive Landscape
   12.1 Amgen
   12.2 AVAX Technologies
   12.3 Corixa
   12.4 GlaxoSmithKline
   12.5 Gradalis
   12.6 Immunocore
   12.7 Immune Design
   12.8 Merck
   12.9 MolMed
   12.10 NeoStem Oncology

List of Figures:

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Functions of Skin
Figure 3-2: Layers of Skin
Figure 3-3: Types of Skin Cancer
Figure 3-4: Factors Causing Skin Cancer
Figure 4-1: Types of Skin Cancer Treatment
Figure 4-2: Implantable Skin Cancer Vaccine
Figure 4-3: Mechanism of Oncolytic Skin Cancer Vaccine
Figure 4-4: Mechanism of T-VEC Skin Cancer Vaccine
Figure 5-1: Global Skin Cancer Vaccines Pipeline (%), 2015
Figure 5-2: Global Skin Cancer Vaccines Pipeline (Number), 2015
Figure 5-3: No Development Reported in Skin Cancer Vaccines Pipeline (%), 2015
Figure 5-4: No Development Reported in Skin Cancer Vaccines Pipeline (Number), 2015
Figure 5-5: Discontinued Skin Cancer Vaccines in Pipeline (%), 2015
Figure 5-6: Discontinued Skin Cancer Vaccines in Pipeline (Number), 2015
Figure 6-1: Drivers for Skin Cancer Vaccine
Figure 6-2: Skin Cancer Vaccine Market Challenges
Figure 7-1: Overview of Personalized Cancer Vaccines Development
Figure 7-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 7-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3100998/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Skin Cancer Vaccine Market & Pipeline Insight 2015
Web Address: http://www.researchandmarkets.com/reports/3100998/
Office Code: SCH3JAH3

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1500</td>
</tr>
<tr>
<td>CD-ROM</td>
<td></td>
<td>USD 1800 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Hard Copy</td>
<td></td>
<td>USD 2400 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprise wide</td>
<td></td>
<td>USD 3000</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ____________________________ Last Name: ____________________________
Email Address: *
Job Title: ________________________________
Organisation: ____________________________
Address: ________________________________
City: ___________________________________
Postal / Zip Code: ________________________
Country: ________________________________
Phone Number: ___________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
- Account number 833 130 83
- Sort code 98-53-30
- Swift code ULSBIE2D
- IBAN number IE78ULSB98533083313083
- Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp